[SCHEDULE 13G/A] Outlook Therapeutics, Inc. SEC Filing
Great Point Partners, LLC together with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl report beneficial ownership of 2,220,000 shares of Outlook Therapeutics, Inc. common stock, representing 4.99% of the outstanding shares based on 42,192,728 shares reported by the issuer. The holdings consist of warrants to purchase 2,220,000 shares, which are treated as beneficially owned but are subject to an exercise restriction (a Beneficial Ownership Cap) that prevents exercise if it would increase ownership above 9.99%.
The reporting persons disclose shared voting and dispositive power over the 2,220,000 shares and state the position is not held to influence control of the issuer. The filing is a joint Schedule 13G/A and includes a Joint Filing Agreement executed August 14, 2025.
Great Point Partners, LLC insieme al Dr. Jeffrey R. Jay, M.D., e alla Sig.ra Lillian Nordahl dichiarano la titolarit脿 effettiva di 2.220.000 azioni ordinarie di Outlook Therapeutics, Inc., rappresentanti 4,99% delle azioni in circolazione in base alle 42.192.728 azioni riportate dall'emittente. Le partecipazioni consistono in warrant per l'acquisto di 2.220.000 azioni, che sono considerati di propriet脿 effettiva ma soggetti a una restrizione di esercizio (un Beneficial Ownership Cap) che impedisce l'esercizio se aumenterebbe la partecipazione oltre il 9,99%.
I soggetti dichiaranti comunicano di avere il potere di voto e dispositivi condivisi sulle 2.220.000 azioni e affermano che la posizione non 猫 detenuta con l'intento di influenzare il controllo dell'emittente. Il deposito 猫 un Schedule 13G/A congiunto e include un Accordo di Deposito Congiunto eseguito il 14 agosto 2025.
Great Point Partners, LLC junto con el Dr. Jeffrey R. Jay, M.D., y la Sra. Lillian Nordahl informan la propiedad beneficiaria de 2.220.000 acciones ordinarias de Outlook Therapeutics, Inc., que representan el 4,99% de las acciones en circulaci贸n seg煤n las 42.192.728 acciones reportadas por el emisor. Las tenencias consisten en warrants para comprar 2.220.000 acciones, que se tratan como propiedad beneficiaria pero est谩n sujetos a una restricci贸n de ejercicio (un Beneficial Ownership Cap) que impide el ejercicio si aumentar铆a la participaci贸n por encima del 9,99%.
Los declarantes divulgan el poder de voto y dispositive compartido sobre las 2.220.000 acciones y declaran que la posici贸n no se mantiene para influir en el control del emisor. La presentaci贸n es un Schedule 13G/A conjunto e incluye un Acuerdo de Presentaci贸n Conjunta ejecutado el 14 de agosto de 2025.
Great Point Partners, LLC電� Dr. Jeffrey R. Jay, M.D. 氚� Ms. Lillian Nordahl鞕� 頃粯 Outlook Therapeutics, Inc. 氤错喌欤� 2,220,000欤茧ゼ 鞁れ唽鞙犽 氤搓碃頃橂┌, 鞚措姅 氚滍枆靷皜 氤搓碃頃� 42,192,728欤茧ゼ 旮办鞙茧 氚滍枆欤检嫕鞚� 4.99%鞐� 頃措嫻頃╇媹雼�. 氤挫湢 雮挫棴鞚� 2,220,000欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸鸽 甑劚霅橃柎 鞛堨溂氅�, 鞚措姅 鞁れ唽鞙犽 臧勳＜霅橃毵� 頄夓偓 鞝滍暅(鞚茧獏 Beneficial Ownership Cap)鞚� 鞛堨柎 氤挫湢 牍勳鞚� 9.99%毳� 齑堦臣頃橁矊 霅橂姅 瓴届毎 頄夓偓臧� 鞝滍暅霅╇媹雼�.
氤搓碃鞚胳潃 2,220,000欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 鞛堨潓鞚� 瓿店皽頃橂┌, 頃措嫻 歆�攵勳澊 氚滍枆靷潣 歆�氚办棎 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�. 頃措嫻 鞝滌稖鞚� 瓿惦彊 Schedule 13G/A鞚措┌ 2025雲� 8鞗� 14鞚检棎 觳搓舶霅� 瓿惦彊 鞝滌稖 頃╈潣靹滊ゼ 韽暔頃╇媹雼�.
Great Point Partners, LLC, conjointement avec le Dr Jeffrey R. Jay, M.D., et Mme Lillian Nordahl, d茅clarent la propri茅t茅 b茅n茅ficiaire de 2 220 000 actions ordinaires d'Outlook Therapeutics, Inc., soit 4,99% des actions en circulation sur la base des 42 192 728 actions signal茅es par l'茅metteur. Les participations se composent de bons de souscription portant sur 2 220 000 actions, consid茅r茅s comme d茅tenus b茅n茅fiquement mais soumis 脿 une restriction d'exercice (un Beneficial Ownership Cap) emp锚chant l'exercice si cela faisait d茅passer 9,99% de d茅tention.
Les d茅clarants indiquent d茅tenir le pouvoir de vote et de disposition partag茅 sur les 2 220 000 actions et pr茅cisent que la position n'est pas d茅tenue dans le but d'influencer le contr么le de l'茅metteur. Le d茅p么t est un Schedule 13G/A conjoint et inclut un Accord de D茅p么t Conjoints sign茅 le 14 ao没t 2025.
Great Point Partners, LLC berichtet zusammen mit Dr. Jeffrey R. Jay, M.D., und Frau Lillian Nordahl 眉ber das wirtschaftliche Eigentum an 2.220.000 Stammaktien von Outlook Therapeutics, Inc., was 4,99% der ausgegebenen Aktien entspricht, basierend auf 42.192.728 vom Emittenten gemeldeten Aktien. Die Best盲nde bestehen aus Warrants zum Erwerb von 2.220.000 Aktien, die zwar als wirtschaftliches Eigentum gelten, aber einer Aus眉bungsbeschr盲nkung (einem Beneficial Ownership Cap) unterliegen, die eine Aus眉bung verhindert, wenn dadurch der Anteil 眉ber 9,99% steigen w眉rde.
Die meldenden Personen geben an, 眉ber die 2.220.000 Aktien geteilte Stimm- und Verf眉gungsgewalt zu verf眉gen und erkl盲ren, dass die Position nicht gehalten wird, um die Kontrolle des Emittenten zu beeinflussen. Die Meldung ist ein gemeinsames Schedule 13G/A und enth盲lt eine am 14. August 2025 unterzeichnete gemeinsame Einreichungsvereinbarung.
- Beneficial ownership disclosed transparently at 2,220,000 shares (4.99%), meeting SEC reporting requirements
- Holdings are below 5% threshold, indicating passive disclosure under Schedule 13G rather than an active 13D control filing
- Exercise cap (9.99%) limits potential immediate increase in ownership, reducing near-term control risk
- Shares are held via warrants, so ownership is contingent on exercise conditions and not immediate common stock ownership
- No sole voting or dispositive power reported鈥攁ll power is shared, which may complicate decision-making among reporting persons
Insights
TL;DR: Reported stake equals 4.99% via warrants, below 5% active ownership threshold, limited by a 9.99% exercise cap.
The filing shows an economic exposure to Outlook Therapeutics through warrants for 2,220,000 shares, recorded as beneficial ownership but constrained by the Beneficial Ownership Cap. Because the reported percentage is 4.99%, the position remains within the disclosure band for passive holdings under Rule 13d-1(b). Shared voting and dispositive power indicate coordinated control rights among the reporting persons rather than sole control. For investors, this is a material ownership disclosure but not a control-threatening accumulation.
TL;DR: Joint filing clarifies responsibilities; signature and agreement indicate governance transparency but no change-of-control intent.
The Joint Filing Agreement and certifications affirm that the reporting persons are filing jointly and disclaim intent to influence control, aligning with Schedule 13G treatment. The restriction on exercise of the warrants (to avoid exceeding 9.99%) reduces immediate potential for governance influence. The shared voting power should be monitored for any future conversion/exercise events, but currently the filing signals routine disclosure rather than an activist or control campaign.
Great Point Partners, LLC insieme al Dr. Jeffrey R. Jay, M.D., e alla Sig.ra Lillian Nordahl dichiarano la titolarit脿 effettiva di 2.220.000 azioni ordinarie di Outlook Therapeutics, Inc., rappresentanti 4,99% delle azioni in circolazione in base alle 42.192.728 azioni riportate dall'emittente. Le partecipazioni consistono in warrant per l'acquisto di 2.220.000 azioni, che sono considerati di propriet脿 effettiva ma soggetti a una restrizione di esercizio (un Beneficial Ownership Cap) che impedisce l'esercizio se aumenterebbe la partecipazione oltre il 9,99%.
I soggetti dichiaranti comunicano di avere il potere di voto e dispositivi condivisi sulle 2.220.000 azioni e affermano che la posizione non 猫 detenuta con l'intento di influenzare il controllo dell'emittente. Il deposito 猫 un Schedule 13G/A congiunto e include un Accordo di Deposito Congiunto eseguito il 14 agosto 2025.
Great Point Partners, LLC junto con el Dr. Jeffrey R. Jay, M.D., y la Sra. Lillian Nordahl informan la propiedad beneficiaria de 2.220.000 acciones ordinarias de Outlook Therapeutics, Inc., que representan el 4,99% de las acciones en circulaci贸n seg煤n las 42.192.728 acciones reportadas por el emisor. Las tenencias consisten en warrants para comprar 2.220.000 acciones, que se tratan como propiedad beneficiaria pero est谩n sujetos a una restricci贸n de ejercicio (un Beneficial Ownership Cap) que impide el ejercicio si aumentar铆a la participaci贸n por encima del 9,99%.
Los declarantes divulgan el poder de voto y dispositive compartido sobre las 2.220.000 acciones y declaran que la posici贸n no se mantiene para influir en el control del emisor. La presentaci贸n es un Schedule 13G/A conjunto e incluye un Acuerdo de Presentaci贸n Conjunta ejecutado el 14 de agosto de 2025.
Great Point Partners, LLC電� Dr. Jeffrey R. Jay, M.D. 氚� Ms. Lillian Nordahl鞕� 頃粯 Outlook Therapeutics, Inc. 氤错喌欤� 2,220,000欤茧ゼ 鞁れ唽鞙犽 氤搓碃頃橂┌, 鞚措姅 氚滍枆靷皜 氤搓碃頃� 42,192,728欤茧ゼ 旮办鞙茧 氚滍枆欤检嫕鞚� 4.99%鞐� 頃措嫻頃╇媹雼�. 氤挫湢 雮挫棴鞚� 2,220,000欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸鸽 甑劚霅橃柎 鞛堨溂氅�, 鞚措姅 鞁れ唽鞙犽 臧勳＜霅橃毵� 頄夓偓 鞝滍暅(鞚茧獏 Beneficial Ownership Cap)鞚� 鞛堨柎 氤挫湢 牍勳鞚� 9.99%毳� 齑堦臣頃橁矊 霅橂姅 瓴届毎 頄夓偓臧� 鞝滍暅霅╇媹雼�.
氤搓碃鞚胳潃 2,220,000欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 鞛堨潓鞚� 瓿店皽頃橂┌, 頃措嫻 歆�攵勳澊 氚滍枆靷潣 歆�氚办棎 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�. 頃措嫻 鞝滌稖鞚� 瓿惦彊 Schedule 13G/A鞚措┌ 2025雲� 8鞗� 14鞚检棎 觳搓舶霅� 瓿惦彊 鞝滌稖 頃╈潣靹滊ゼ 韽暔頃╇媹雼�.
Great Point Partners, LLC, conjointement avec le Dr Jeffrey R. Jay, M.D., et Mme Lillian Nordahl, d茅clarent la propri茅t茅 b茅n茅ficiaire de 2 220 000 actions ordinaires d'Outlook Therapeutics, Inc., soit 4,99% des actions en circulation sur la base des 42 192 728 actions signal茅es par l'茅metteur. Les participations se composent de bons de souscription portant sur 2 220 000 actions, consid茅r茅s comme d茅tenus b茅n茅fiquement mais soumis 脿 une restriction d'exercice (un Beneficial Ownership Cap) emp锚chant l'exercice si cela faisait d茅passer 9,99% de d茅tention.
Les d茅clarants indiquent d茅tenir le pouvoir de vote et de disposition partag茅 sur les 2 220 000 actions et pr茅cisent que la position n'est pas d茅tenue dans le but d'influencer le contr么le de l'茅metteur. Le d茅p么t est un Schedule 13G/A conjoint et inclut un Accord de D茅p么t Conjoints sign茅 le 14 ao没t 2025.
Great Point Partners, LLC berichtet zusammen mit Dr. Jeffrey R. Jay, M.D., und Frau Lillian Nordahl 眉ber das wirtschaftliche Eigentum an 2.220.000 Stammaktien von Outlook Therapeutics, Inc., was 4,99% der ausgegebenen Aktien entspricht, basierend auf 42.192.728 vom Emittenten gemeldeten Aktien. Die Best盲nde bestehen aus Warrants zum Erwerb von 2.220.000 Aktien, die zwar als wirtschaftliches Eigentum gelten, aber einer Aus眉bungsbeschr盲nkung (einem Beneficial Ownership Cap) unterliegen, die eine Aus眉bung verhindert, wenn dadurch der Anteil 眉ber 9,99% steigen w眉rde.
Die meldenden Personen geben an, 眉ber die 2.220.000 Aktien geteilte Stimm- und Verf眉gungsgewalt zu verf眉gen und erkl盲ren, dass die Position nicht gehalten wird, um die Kontrolle des Emittenten zu beeinflussen. Die Meldung ist ein gemeinsames Schedule 13G/A und enth盲lt eine am 14. August 2025 unterzeichnete gemeinsame Einreichungsvereinbarung.
FAQ
What stake in Outlook Therapeutics (OTLK) do the reporting persons hold?
Are the reported shares actual stock or instruments?
Do the reporting persons have voting control over the shares?
Does this filing indicate an attempt to take control of Outlook Therapeutics?
What is the Beneficial Ownership Cap mentioned in the filing?
